1. Home
  2. NVNI vs CTXR Comparison

NVNI vs CTXR Comparison

Compare NVNI & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

N/A

Current Price

$1.32

Market Cap

15.4M

Sector

N/A

ML Signal

N/A

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

N/A

Current Price

$0.84

Market Cap

16.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NVNI
CTXR
Founded
2019
2007
Country
Brazil
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.4M
16.8M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
NVNI
CTXR
Price
$1.32
$0.84
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
89.2K
585.2K
Earning Date
01-01-0001
06-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.38
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.67
N/A
Revenue Next Year
$26.67
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.63
52 Week High
$4.94
$2.38

Technical Indicators

Market Signals
Indicator
NVNI
CTXR
Relative Strength Index (RSI) 37.16 55.02
Support Level $1.10 $0.66
Resistance Level $1.64 $0.97
Average True Range (ATR) 0.15 0.07
MACD 0.04 0.02
Stochastic Oscillator 35.99 58.09

Price Performance

Historical Comparison
NVNI
CTXR

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: